Vendor review
Shanxi Qianyecao Biotech QYC reviews
Shanxi Qianyecao Biotech QYC reviews from 132 independent lab tests (Retatrutide, Tirzepatide and GHK-Cu): grade A, purity and fill accuracy. Is Shanxi Qianyecao Biotech QYC legit? See what its vials showed.
What the lab tests show
132 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Oct 14, 2026 | Retatrutide | 99.99 % | 18.88 mg of 20 mg (-6 %) | Pass | View |
| Sep 5, 2026 | PT-141 | 99.9 % | 5.7 mg of 5 mg (14 %) | Pass | View |
| Sep 4, 2026 | Sermorelin | 5 mg | Fail | View | |
| Aug 9, 2026 | GHK-Cu | 99.7 % | 53.3 mg of 50 mg (7 %) | Pass | View |
| Aug 5, 2026 | Retatrutide | 69.6 % | 4.89 mg of 5 mg (-2 %) | Pass | View |
| Aug 5, 2026 | Ipamorelin | 97.1 % | 7.31 mg of 5 mg (46 %) | Pass | View |
| Aug 4, 2026 | Retatrutide | 20 mg | Fail | View | |
| Aug 4, 2026 | NAD+ | 88.5 % | 453 mg of 500 mg (-9 %) | Pass | View |
| Jul 23, 2026 | BPC-157 | 99.9 % | 5.08 mg of 5 mg (2 %) | Pass | View |
| Jul 21, 2026 | Tesamorelin | 99.9 % | 5.06 mg of 5 mg (1 %) | Pass | View |
| Jul 21, 2026 | Tirzepatide | 99.9 % | 4.29 mg of 5 mg (-14 %) | Pass | View |
| Jul 17, 2026 | Cagrilintide | 98.9 % | 4.77 mg of 5 mg (-5 %) | Pass | View |
| Jul 17, 2026 | TB-500 | 98.9 % | 4.78 mg of 5 mg (-4 %) | Pass | View |
| Jun 8, 2026 | NAD+ | 99 % | 554 mg of 500 mg (11 %) | Pass | View |
| May 28, 2026 | NAD+ | 92 % | 517 mg of 500 mg (3 %) | Pass | View |
| May 11, 2026 | Tesamorelin | 99.9 % | 11.6 mg of 10 mg (16 %) | Pass | View |
| May 6, 2026 | Ipamorelin | 99.9 % | 10.4 mg of 10 mg (4 %) | Pass | View |
| May 6, 2026 | Tirzepatide | 99.9 % | 23.5 mg of 30 mg (-22 %) | Pass | View |
| May 6, 2026 | Tirzepatide | 99.9 % | 43.3 mg of 40 mg (8 %) | Pass | View |
| May 6, 2026 | Tirzepatide | 99.9 % | 21.4 mg of 20 mg (7 %) | Pass | View |
| May 6, 2026 | BPC-157 | 10 mg | Fail | View | |
| May 6, 2026 | BPC-157 | 10 mg | Fail | View | |
| May 2, 2026 | TB-500 | 99.6 % | 10.9 mg of 10 mg (9 %) | Pass | View |
| Apr 28, 2026 | Retatrutide | 99.9 % | 10.9 mg of 10 mg (9 %) | Pass | View |
| Apr 28, 2026 | Retatrutide | 99.9 % | 4.99 mg of 5 mg (0 %) | Pass | View |
| Apr 28, 2026 | Retatrutide | 99.9 % | 5 mg of 10 mg (-50 %) | Pass | View |
| Apr 28, 2026 | Ipamorelin | 99.4 % | 4.96 mg of 5 mg (-1 %) | Pass | View |
| Apr 28, 2026 | Tirzepatide | 99.9 % | 10.9 mg of 10 mg (9 %) | Pass | View |
| Apr 28, 2026 | Tesamorelin | 99.7 % | 4.97 mg of 5 mg (-1 %) | Pass | View |
| Apr 28, 2026 | Tesamorelin | 99.9 % | 8.03 mg of 10 mg (-20 %) | Pass | View |
| Apr 28, 2026 | Tesamorelin | 98.5 % | 19.4 mg of 20 mg (-3 %) | Pass | View |
| Apr 28, 2026 | GHK-Cu | 99.9 % | 45.9 mg of 50 mg (-8 %) | Pass | View |
| Apr 28, 2026 | BPC-157 | 99.9 % | 5.02 mg of 5 mg (0 %) | Pass | View |
| Apr 28, 2026 | BPC-157 | 99.9 % | 4.79 mg of 10 mg (-52 %) | Pass | View |
| Apr 28, 2026 | GHK-Cu | 99.9 % | 94.3 mg of 100 mg (-6 %) | Pass | View |
| Apr 23, 2026 | Tesamorelin | 98.7 % | 7.11 mg of 10 mg (-29 %) | Pass | View |
| Mar 29, 2026 | Tirzepatide | 99.8 % | 5.3 mg of 5 mg (6 %) | Pass | View |
| Mar 19, 2026 | Retatrutide | 99.9 % | 18.9 mg of 20 mg (-6 %) | Pass | View |
| Mar 12, 2026 | Retatrutide | 95.8 % | 4.8 mg of 5 mg (-4 %) | Pass | View |
| Mar 12, 2026 | Tesamorelin | 99.6 % | 5.19 mg of 5 mg (4 %) | Pass | View |
| Mar 12, 2026 | Cagrilintide | 94.1 % | 4.99 mg of 5 mg (0 %) | Pass | View |
| Mar 6, 2026 | Retatrutide | 99.9 % | 55.7 mg of 60 mg (-7 %) | Pass | View |
| Mar 6, 2026 | Retatrutide | 99.9 % | 27.8 mg of 30 mg (-7 %) | Pass | View |
| Mar 6, 2026 | NAD+ | 99.4 % | 1320 mg of 1000 mg (32 %) | Pass | View |
| Mar 6, 2026 | Sermorelin | 99.9 % | 10.4 mg of 10 mg (4 %) | Pass | View |
| Mar 4, 2026 | Retatrutide | 99.7 % | 11.8 mg of 15 mg (-21 %) | Pass | View |
| Mar 3, 2026 | Retatrutide | 99.9 % | 11 mg of 10 mg (10 %) | Pass | View |
| Mar 2, 2026 | Retatrutide | 99.9 % | 14.8 mg of 15 mg (-1 %) | Pass | View |
| Mar 2, 2026 | GHK-Cu | 99.82 % | 53.3 mg of 50 mg (7 %) | Pass | View |
| Mar 1, 2026 | Retatrutide | 99.6 % | 10.8 mg of 10 mg (8 %) | Pass | View |
| Mar 1, 2026 | Retatrutide | 99.7 % | 18.6 mg of 20 mg (-7 %) | Pass | View |
| Mar 1, 2026 | Retatrutide | 99.7 % | 29.8 mg of 30 mg (-1 %) | Pass | View |
| Mar 1, 2026 | Tirzepatide | 99.8 % | 27.5 mg of 30 mg (-8 %) | Pass | View |
| Mar 1, 2026 | PT-141 | 99.9 % | 11.7 mg of 10 mg (17 %) | Pass | View |
| Feb 26, 2026 | Sermorelin | 99.87 % | 11.4 mg of 10 mg (14 %) | Pass | View |
| Feb 22, 2026 | Retatrutide | 99.14 % | 21.5 mg of 20 mg (8 %) | Pass | View |
| Feb 22, 2026 | GHK-Cu | 99.73 % | 50.1 mg of 50 mg (0 %) | Pass | View |
| Feb 22, 2026 | Retatrutide | 99.9 % | 64.5 mg of 60 mg (8 %) | Pass | View |
| Feb 20, 2026 | Retatrutide | 99.79 % | 10.8 mg of 10 mg (8 %) | Pass | View |
| Feb 20, 2026 | Retatrutide | 99.9 % | 13.6 mg of 10 mg (36 %) | Pass | View |
What Shanxi Qianyecao Biotech QYC sells
No current listings on record.
About Shanxi Qianyecao Biotech QYC
Finnrick has tested 132 samples from Shanxi Qianyecao Biotech QYC across 11 products.